Table 2 In-hospital outcomes by COVID-19 infection status
|  | COVID-positive (n = 264) | COVID-negative (n = 706) | p value |
|---|---|---|---|
CAG | 262 (99.2) | 688 (97.5) | 0.135 |
PCI | 189 (71.6) | 583 (82.6) | < 0.001 |
IABP/ECMO | 18 (6.8) | 35 (5.3) | 0.474 |
Coronary angiographic measures | Â | Â | Â |
 Multivessel CAD | 180 (68.7) | 298 (64.5) | 0.287 |
 Coronary thrombosis | 117 (44.5) | 207 (44.8) | 0.996 |
 Post-procedural TIMI flow grade 0–2 | 24 (11.1) | 47 (8.3) | 0.273 |
 No-reflow | 5 (2.4) | 14 (2.5) | 1 |
 Slow-flow | 19 (8.8) | 33 (5.8) | 0.180 |
PCI-associated complications | Â | Â | Â |
 Coronary artery dissection | 1 (0.4) | 2 (0.4) | 1 |
 Coronary artery perforation | 1 (0.4) | 0 (0.0) | 0.781 |
 Cardiac arrest | 1 (0.4) | 6 (1.3) | 0.402 |
 Emergent revascularization | 3 (1.1) | 7 (1.5) | 0.906 |
 Peri-procedural mortality | 0 (0.0) | 1 (0.2) | 1 |
AMI-associated complications | Â | Â | Â |
 Cardiac tamponade | 3 (1.1) | 1 (0.2) | 0.275 |
 Papillary muscle rupture | 0 (0.0) | 0 (0.0) | NA |
 Pericardial effusion | 39 (14.8) | 62 (13.4) | 0.686 |
Arrhythmia | Â | Â | Â |
 AF | 14 (5.3) | 39 (5.5) | 1 |
 VT or VF | 15 (5.7) | 27 (5.8) | 1 |
 Sinus bradycardia or sinus pause | 6 (2.3) | 11 (2.4) | 1 |
 Third-degree AVB | 5 (1.9) | 12 (2.6) | 0.734 |
 Defibrillation | 7 (2.7) | 15 (3.3) | 0.825 |
LVEF | 50.00 [45.00, 57.00] | 53.00 [45.00, 60.00] | 0.002 |
LVSD | 108 (49.8) | 261 (39.8) | 0.012 |
Pre-discharge Killip class 3–4 | 29 (11.0) | 52 (11.4) | 0.977 |
Cardiopulmonary resuscitation | 10 (3.8) | 20 (4.3) | 0.877 |
In-hospital mortality | 5 (1.9) | 10 (1.4) | 0.799 |
Gastrointestinal bleeding | 25 (10.7) | 48 (10.6) | 1 |
Cerebrovascular events | 2 (0.8) | 2 (0.4) | 0.964 |
AKI | 12 (4.6) | 23 (5.0) | 0.942 |
Length of CCU stay (days, median [IQR]) | 2.00 [0.00, 5.00] | 3.00 [1.00, 5.00] | 0.002 |
Length of Hospital stay (days, median [IQR]) | 9.00 [7.00, 13.00] | 10.00 [8.00, 13.00] | 0.240 |
Hospital costs (10,000 CNY, median [IQR]) | 3.39 [2.52, 4.62] | 3.45 [2.72, 4.75] | 0.249 |